Canaccord Reiterates Rating On CloudMD After Quarterly Results

On August 25, CloudMD Software & Services (TSXV: DOC) reported their second quarter financial results. The company announced record revenues of $15.7 million, up 461% year over year. Gross profit came in at $5.55 million, up 439% and gross margin was 35.5%. The company lost $6.15 million on the bottom line, resulting in earnings per share of ($0.03.) Adjusted EBITDA meanwhile came in at ($0.72) million.

CloudMD currently has 6 analysts covering the stock with an average 12-month price target of $3.97, or an 112% upside. The street high sits at $5.00 from Stephens Inc, while the lowest comes in at $3.30. Out of the 6 analysts, 2 have strong buy ratings and 4 have buy ratings.

In Canaccord’s note to investors, they reiterated their $3.50 12-month price target and speculative buy rating saying that this quarter showed organic growth and that they expect profits in the third quarter.

CloudMD reported $15.7 million in revenue, higher than the Canaccord $15.3 million estimate and $15.0 million street estimate. Adjusted EBITDA also came in better than expected. Canaccord says that revenue benefitted from partial contributions from its Aspiria, Rx Infinity, VisionPros, and Ocdidium deals closing in the middle of the quarter.

Canaccord says that the company’s 9% sequential organic growth is notable as the company has been in roll-up mode for a long time, so it was hard to get accurate organic growth data. Canaccord adds, “The company has a strong sales pipeline of multi-year engagement opportunities, expecting two additional employers to go live in Q3.” Canaccord does believe that the company has enough cash to execute on any new M&A that comes up, as the company ended the quarter with $61 million in cash, $25 million in debt and $62 million in a credit facility.

Below you can see Canaccord’s updated third quarter, full-year 2021, and 2022 estimates. They have modified their estimates as they expect a more conservative ramp into profitability.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

Stifel-GMP: Canopy Growth CEO’s Legacy is “Poor Execution, Misallocated Capital, and Mismanaged Expectations.”

Earlier this month, Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) reported their fiscal second-quarter 2022...

Sunday, November 21, 2021, 12:03:00 PM

Nevada Copper: Haywood Drops Target To $0.20 After Yet Another Management Changeup

On August 13, Nevada Copper Corp. (TSX: NCU) announced their second quarter financial results. The...

Wednesday, August 18, 2021, 04:50:00 PM

Haywood Slashes Pieridae Energy Price Target After LNG Project Goes Bust, CFO Leaves

On July 2, Pieridae Energy (TSX: PEA) announced that they would be effectively suspending their...

Saturday, July 10, 2021, 02:24:00 PM

Topaz Energy Sees BMO Resume Analyst Coverage

On June 8th, Topaz Energy Corp. (TSX: TPZ) had a flurry of news releases. The...

Friday, June 11, 2021, 04:16:00 PM

Canaccord Raises Price Target On Teranga Gold Following Pre-Feasibility Study

Last night, Teranga Gold Corp (TSX: TGZ) announced the results of the Sabodala-Massawa Gold Complex’s...

Monday, July 27, 2020, 06:43:23 PM